Identification of a claims data "signature" and economic consequences for treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 63, Issue 8, 2002, Pages 717-726

  Corey Lisle, Patricia K ^a   Birnbaum, Howard G ^a   Greenberg, Paul E ^a   Marynchenko, Maryna B ^a   Claxton, Ami J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; ALGORITHM; ARTICLE; COST BENEFIT ANALYSIS; DEPRESSION; DISABILITY; FEMALE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION;

EID: 0036677169     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0810     Document Type: Article

References (23)

1. Social functioning in depression: A review
2. The economic burden of depression in 1990
3. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
4. Practice guidelines for the treatment of patients with major depressive disorder
5. Social functioning and the treatment of depression
6. Effectiveness and economic impact of antidepressant medications: A review
7. Patterns of antidepressant use and their relationship to costs of care
8. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization
9. Recovery from depression, work productivity, and health care costs among primary care patients
10. Consensus guidelines in the treatment of major depressive disorder
11. Treatment resistant depression: Methodological overview and operational criteria
12. Venlafaxine and treatment-resistant depression
13. Treatment-resistant depression: A critique of current approaches
14. Treatment-resistant depression
15. Treatment-resistant depression: Progress and limitations
16. The deliberate misdiagnosis of major depression in primary care
17. The NIMH depression awareness, recognition, and treatment programs: Structure, aims, and scientific basis
18. Use of an integrated health data warehouse to measure the employer costs of five chronic disease states
19. The costs of cancer to a major employer in the United States: A case-control analysis
20. Disability and depression among high utilizers of health care: A longitudinal analysis
21. The relationship between depression and length of stay in the general hospital patient